Form 4: MaxCyte Director Stanley Erck Receives Annual Equity Grant

Director Stanley C Erck received an annual equity grant from MaxCyte, Inc. consisting of restricted stock units and stock options.

Summary

• On June 11, 2024, Stanley C Erck, a director of MaxCyte, Inc. (MXCT), received an annual equity grant.
• The grant included 21,367 restricted stock units (RSUs) and stock options for 40,701 shares.
• The RSUs represent a contingent right to receive one share of MaxCyte's common stock each.
• The stock options have an exercise price of $4.68 and expire on June 10, 2034.
• The shares underlying the RSU grant vest on June 11, 2025, contingent upon continuous service as a director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices and aligns director interests with shareholders.

Positives

• The equity grant aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the equity grant.

Industry Context

Equity grants to directors are a common practice to incentivize and align their interests with the long-term performance of the company. This is a standard component of director compensation packages in publicly traded companies.

Comparison to Industry Standards

• Equity grants for non-employee directors are a common practice across the biotechnology industry.
• Companies like CRISPR Therapeutics and Editas Medicine also provide similar equity-based compensation to their directors.
• The size and vesting schedule of the grant are generally aligned with industry benchmarks for companies of similar size and stage of development.

Stakeholder Impact

• The equity grant aligns the director's interests with those of the shareholders, potentially leading to better decision-making for the company's long-term success.

Key Dates